Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4990-4998

  Queener, S F ^a   Cody, V ^b,c   Pace, J ^b,c   Torkelson, P ^a   Gangjee, A ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIMETHOPRIM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONFORMATIONAL TRANSITION; ENZYME BINDING; MUTATION; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE; WILD TYPE;

MOLECULAR STRUCTURE; PNEUMOCYSTIS JIROVECII; PROTEIN STRUCTURE, SECONDARY; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM; TRIMETHOPRIM RESISTANCE;

EID: 84884268397     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01161-13     Document Type: Article

References (25)

1. Iliades P, Meshnick SR, Macreadie IG. 2005. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob. Agents Chemother. 49:741-748.
2. Nahimana A, Rabodonirina M, Bille J, Francioli P, Houser PM. 2004. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob. Agents Chemother. 48:4301-4305.
3. Takahashi T, Endo T, Nakamura T, Sakashita H, Kimura K, Ohnishi K, Kitamura Y, Iwamoto A. 2002. Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. Hominis in Japan. J. Med. Microbiol. 51:510-515.
4. Takahashi T. 2009. Mutations of drug target molecules in Pneumocystis jirovecii isolates and future investigations. Jpn. J. Med. Mycol. 50:67-73.
5. Robberts FJL, Chalkley LJ, Weyer K, Goussard P, Liebowitz LD. 2005. Dihydropteroate synthase and novel dihydrofolate reductase gene mutations in strains of Pneumocystis jirovecii from South Africa. J. Clin. Microbiol. 43:1443-1444.
6. Costa MC, Esteves F, Antunes F, Matos O. 2006. Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. J. Antimicrob. Chemother. 58:1246-1249.
7. Ma L, Borio L, Masur H, Kovacs JA. 1999. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180:1969-1978.
8. Siripattanapipong S, Leelavoova S, Mungthin M, Worapong J, Tan-Ariya P. 2008. Study of DHPS and DHFR genes of Pneumocystis jirovecii in Thai HIV-infected patients. Med. Mycol. 46:389-392.
9. Esteves F, Gaspar J, De Sousa B, Antunes F, Mansinho K, Matos O. 2011. Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCRsingle-base-extension methodology. J. Clin. Microbiol. 49:1810-1815.
10. Munoz C, Zuluaga A, Restrepo A, Tobon A, Cano LE, Gonzalez A. 2012. Molecular dignosis and detection of Pneumocystis jirovecii DHPS and DHFR genotypes in respiratory specimens from Colombian patients. Diagn. Microbiol. Infect. Dis. 72:204-213.
11. Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A. 2009. Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes. Biochemistry 48:1702-1711.
12. Margosiak SA, Appleman JR, Santi DV, Blakley RL. 1993. Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: catalytic properties and interaction with antifolates. Arch. Biochem. Biophys. 305:499-508.
13. Segel IH. 1975. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley-Interscience, New York, NY.
14. Gangjee A, Adair OO, Queener SF. 2003. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]-pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J. Med. Chem. 46:5074-5082.
15. Cody V, Pace J, Queener SF, Adair OO, Gangjee A. 2013. Kinetic and structural analysis for potent antifolate inhibition of Pneumocystis jirovecii, Pneumocystis carinii, and human dihydrofolate reductase and their active-site variants. Antimicrob. Agents Chemother. 57:2669-2677.
16. Cody V, Galitsky N, Rak D, Luft JR, Pangborn W, Queener SF. 1999. Ligand induced conformational changes in the crystal structures of Pneumcystis carinii dihydrofolate reductase complexes with folate and NADP Biochemistry 38:4303-4312.
17. Cody V, Freindorf M, Furlani T, Queener SF, Gangjee A. 2009. Correlations of the kinetic properties and computational QM/MM modeling of potent dihydrofolate reductase inhibitors, abstr 2458. Abstr. 100th Annu. Meet. Am. Assoc. Cancer Researchers.
18. Champness JN, Achari A, Ballantine SP, Bryant PK, Delves CJ, Stammers DK. 1994. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9A resolution. Structure 2:915-924.
19. Ripamonti C, Orenstein A, Kutty G, Huang L, Schuhegger R, Sing A, Fantoni G, Atzori C, Vinton C, Huber C, Conville PS, Kovacs JA. 2009. Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jirovecii isolates. J. Infect. Dis. 200: 1616-1622.
20. Choukri F, Menotti J, Sarfati C, Lucet JC, Nevez G, Garin YJF, Derouin F, Totet A. 2010. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin. Infect. Dis. 51:259-265.
21. Hauser PM, Nahimana A, Taffe P, Weber R, Francioli P, Bille J, Rabodonirina M. 2010. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. Clin. Infect. Dis. 51:e28-e33.
22. Watson M, Liu JW, Ollis D. 2007. Directed evolution of trimethoprim resistance in Escherichia coli. FEBS J. 274:2661-2671.
23. Dale GE, Broger C, D'Arcy A, Hartman PG, DeHoogt R, Jolidon S, Kompis I, Labhardt AM, Langen H, Locher H, Page MGP, Stuber D, Then RL, Wipf B, Oefner C. 1997. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 266:23-30.
24. Maskell JP, Sefton AM, Hall LMC. 2001. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1104-1108.
25. Pikis A, Donkersloot JA, Rodriguez WJ, Keith JM. 1998. A conservative amino acid mutation in the chromosomal dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J. Infect. Dis. 178: 700-706.